Loading company
Loading
Latest quarter · Q3 FY2026
Millions- Total revenues
- 1
- Operating income
- (42)
- Net income
- (40)
Entrada Therapeutics, Inc. (TRDA) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $25.4 million | $210.8 million | -87.9% | 10-K 2026-02-26 · proof |
| Operating income | -$157.9 million | $47 million | -435.9% | 10-K 2026-02-26 · proof |
| Net income | -$143.8 million | $65.6 million | -319% | 10-K 2026-02-26 · proof |
| Cash from operating activities | -$128.5 million | -$41.6 million | 10-K 2026-02-26 · proof | |
| Free cash flow | -$129.6 million | -$44.7 million | 10-K 2026-02-26 · proof | |
| Total assets | $377.4 million | $526.3 million | -28.3% | 10-K 2026-02-26 · proof |
| Total liabilities | $71.2 million | $97.6 million | -27% | 10-K 2026-02-26 · proof |
| Cash and cash equivalents | $90.4 million | $101.2 million | -10.7% | 10-K 2026-02-26 · proof |
- What was Entrada Therapeutics, Inc. (TRDA)'s revenue in fiscal 2025?
- Entrada Therapeutics, Inc. (TRDA) reported revenue of $25.4 million for fiscal 2025 (the year ended Dec 31, 2025), against $210.8 million the year before (-87.9%). Source: the 10-K filed with the SEC on Feb 26, 2026. SEC
- What was Entrada Therapeutics, Inc. (TRDA)'s operating income in fiscal 2025?
- Entrada Therapeutics, Inc. (TRDA) reported operating income of -$157.9 million for fiscal 2025 (the year ended Dec 31, 2025), against $47 million the year before (-435.9%). Source: the 10-K filed with the SEC on Feb 26, 2026. SEC
- What was Entrada Therapeutics, Inc. (TRDA)'s net income in fiscal 2025?
- Entrada Therapeutics, Inc. (TRDA) reported net income of -$143.8 million for fiscal 2025 (the year ended Dec 31, 2025), against $65.6 million the year before (-319%). Source: the 10-K filed with the SEC on Feb 26, 2026. SEC
- What was Entrada Therapeutics, Inc. (TRDA)'s cash from operating activities in fiscal 2025?
- Entrada Therapeutics, Inc. (TRDA) reported cash from operating activities of -$128.5 million for fiscal 2025 (the year ended Dec 31, 2025), against -$41.6 million the year before. Source: the 10-K filed with the SEC on Feb 26, 2026. SEC
- What was Entrada Therapeutics, Inc. (TRDA)'s free cash flow in fiscal 2025?
- Entrada Therapeutics, Inc. (TRDA) reported free cash flow of -$129.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$44.7 million the year before. Source: the 10-K filed with the SEC on Feb 26, 2026. SEC
- What are Entrada Therapeutics, Inc. (TRDA)'s total assets?
- As of Dec 31, 2025, Entrada Therapeutics, Inc. (TRDA) reported total assets of $377.4 million, against $526.3 million a year earlier (-28.3%). Source: the 10-K filed with the SEC on Feb 26, 2026. SEC
- What are Entrada Therapeutics, Inc. (TRDA)'s total liabilities?
- As of Dec 31, 2025, Entrada Therapeutics, Inc. (TRDA) reported total liabilities of $71.2 million, against $97.6 million a year earlier (-27%). Source: the 10-K filed with the SEC on Feb 26, 2026. SEC
- What are Entrada Therapeutics, Inc. (TRDA)'s cash and cash equivalents?
- As of Dec 31, 2025, Entrada Therapeutics, Inc. (TRDA) reported cash and cash equivalents of $90.4 million, against $101.2 million a year earlier (-10.7%). Source: the 10-K filed with the SEC on Feb 26, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:TRDA&period_type=annual&limit=5"Information only, not investment advice.